The prevalence of metabolic syndrome in the Krasnoyarsk Krai population and the features of its association with hyperuricemia

Aim. To study the prevalence of metabolic syndrome (MS) and its components, as well as their relationship with hyperuricemia (HU) in a representative sample of the Krasnoyarsk Krai.

Material and methods. As part of a multicenter epidemiological study ESSE-RF, a representative sample of 1603 residents of the Krasnoyarsk Krai aged 25-64 was randomized. All subjects underwent a questionnaire survey, anthropometry, office blood pressure (BP) measurement, determining the levels of blood lipids, plasma glucose and serum uric acid. MS was diagnosed according to the modified NCEP ATP III criteria (2005). Statistical processing was carried out using the software package IBM SPSS v 22.

Results. The total prevalence of MS was 26,8%; higher in women than in men (29,4% vs 22,9%). With age, the prevalence of MS significantly increased — from 6,9% in subjects aged 25-34 years to 45,2% in people 55-64 years old. The prevalence of MS was significantly higher among rural residents compared with urban ones (36,8% vs 23,1%). Education level significantly affected prevalence of MS: in people with basic education, MS was found in 35,7%, with secondary — in 30,3%, with higher — in 17,8%. Regression analysis showed that hypertriglyceridemia, blood pressure >130/85 mm Hg and glucose ≥5,6 mmol/l were a significant predictors of HU in all subjects. For men, significant predictors of HU were hypertriglyceridemia and abdominal obesity, and for women — glucose ≥5,6 mmol/l and lipid-lowering therapy.

Conclusion. The prevalence of MS in the Krasnoyarsk Krai, according to the modified NCEP ATP III criteria (2005), is 26,8%. MS is more often recorded in women than in men and in rural residents than in urban ones. With an increase in the education level, MS is less common. With age, the prevalence of MS significantly increases. The correlation of HU is not revealed with all the components of MS and has sex differences.

1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z.

2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. doi:10.1161/CIRCULATIONAHA.109.192644.

3. Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. J Cardiovasc Pharmacol Ther. 2017;22(4):365-7. doi:10.1177/1074248416686187.

4. Bhalwar R. Metabolic syndrome: The Indian public health perspective. Med J Armed Forces India. 2020;76(1):8-16. doi:10.1016/j.mjafi.2019.12.001.

5. Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973-4. doi:10.1001/jama.2015.4260.

6. Scuteri A, Laurent S, Cucca F, et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486-91. doi:10.1177/2047487314525529.

7. Ansarimoghaddam A, Adineh HA, Zareban I, et al. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018;12(2):195-201. doi:10.1016/j.dsx.2017.11.004.

8. Ranasinghe P, Mathangasinghe Y, Jayawardena R, et al. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(1):101. doi:10.1186/s12889-017-4041-1.

9. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14-20. doi:10.1016/j.clindermatol.2017.09.004.

10. Wang H, Zhang H, Sun L, et al. Roles of hyperuricemia in metabolic syndrome and cardiackidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749-63. eCollection 2018.

11. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. PLoS One. 2020;15(2):e0228684. doi:10.1371/journal.pone.0228684.

12. Sumpter NA, Saag KG, Reynolds RJ, et al. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol. 2020;32(2):126-33. doi:10.1097/BOR.0000000000000691.

13. Boytsov SA, Chazov EI, Shlyakhto EV, et al. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Preventive medicine. 2013;16(6):25-34. (In Russ.)

14. He Y, Li Y, Bai G, et al. Prevalence of metabolic syndrome and individual metabolic abnormalities in China, 2002-2012. Asia Pac J Clin Nutr. 2019;28(3):621-33. doi:10.6133/apjcn.201909_28(3).0023.

15. Rotar OP, Libis RA, Isaeva EN, et al. Metabolic syndrome prevalence in russian cities. Russ J Cardiol. 2012;2:55-62. (In Russ.)

16. Pucci G, Alcidi R, Tap L, et al. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 2017;120:34-42. doi:10.1016/j.phrs.2017.03.008.

17. Grinshtein YuI, Shabalin VV, Ruf RR, et al. Relation of hyperuricaemia, renal function and arterial hypertension in a large region of the Eastern Siberia inhabitants. Russ J Cardiol. 2017;6:86-91. (In Russ.) doi:10.15829/1560-4071-2017-6-86-91.

18. Shalnova SA, Deev AD, Artamonov GV, et al. on behalf of the participants of the ESSE-RF study. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Ration Pharmacother Cardiol. 2014;10(1):153-9. (In Russ.)

19. Li L, Song Q, Yang X. Lack of associations between elevated serum uric acid and components of metabolic syndrome such as hypertension, dyslipidemia, and T2DM in overweight and obese Chinese adults. J Diabetes Res. 2019 Dec 4:2019:3175418. doi:10.1155/2019/3175418.